Which startups have raised the most funding in the MedTech market?

Last updated: 13 July 2026

A constantly refreshed list of the top startups in the MedTech market, ranked by cumulative funding raised

market research pitch 2026

In our updated market reports, you will find everything you need

The MedTech market has become one of the largest funding arenas in healthcare, with capital flowing into diagnostics, surgical robotics, neurotechnology, wearables, and cardiovascular devices.

We update this list every month, so the ranking reflects the latest public fundraising data we can verify.

The goal is simple, help founders, investors, and operators quickly see which MedTech startups have raised the most money and where funding is concentrating.

A quick summary table

Metric Value
Most funded startup Grail, $1.7B raised
Second most funded startup Freenome, $1.3B raised
Largest funding round BVI Medical, $1.0B strategic capital raise
Median funding $199.5M
Share of funding captured by the top 10 35.4%
Median time since last round About 18 months
Startups that raised funding in the last 12 months 30 startups
Total MedTech startup funding tracked $30.3B
MedTech startups still active 78 startups
MedTech IPO or acquired outcomes 22 startups

Top startups in the MedTech market ranked by total funding raised

Here is an updated table that ranks the top startups in the MedTech market based on the total amount of funding they have raised to date.

The table also includes the total number of funding rounds, the date and size of the latest round, the financing type (e.g. Series A, equity financing), key investors, the startup’s current status (active, IPO, acquired, or shut down), and a confidence score based on the data collected (we excluded startups with very low data confidence, to make sure everything is reliable).

# Startup What They Do Total Raised ($) Total Rounds Last Round Date Last Round Amount ($) Last Round Type Key Investors Current Stage Confidence
1 Grail Multi-cancer blood testing $1.7B 4 May 2020 $390M Series D PSP Investments, CPP Investments, Illumina IPO Full
2 Freenome Early cancer blood tests $1.3B 7 February 2024 $254M Equity financing Roche, a16z, Quest Diagnostics Active Full
3 Neuralink Implantable brain-computer interfaces $1.3B 5 June 2025 $650M Series E ARK Invest, Founders Fund, Sequoia Capital Active Strong
4 Oura Smart ring health tracking $1.3B 6 October 2025 $900M Series E Fidelity, ICONIQ, Whale Rock Active Strong
5 CMR Surgical Surgical robotics platform $1.1B 5 September 2023 $165M Series D / growth extension Ally Bridge Group, SoftBank Vision Fund 2, Tencent Active Strong
6 Butterfly Network Handheld ultrasound imaging $1.0B 4 January 2025 $76M Public offering Public-market investors, Fidelity, Glenview IPO Strong
7 BVI Medical Ophthalmic surgical devices $1.0B 1 March 2025 $1.0B Strategic capital raise TPG, new investors Acquired Low
8 HeartFlow AI coronary diagnostics $855M 6 April 2023 $215M Series F Bain Capital Life Sciences, Janus Henderson, Baillie Gifford IPO Partial
9 Saluda Medical Closed-loop neuromodulation implants $610M 6 December 2025 $150M IPO Public investors, Wellington Management, Fidelity IPO Partial
10 Insightec MR-guided focused ultrasound $574M 13 June 2024 $150M Series G Fidelity, Nexus Neurotech Ventures, Ally Bridge Group Active Partial
11 Beta Bionics Automated bionic pancreas $570M 9 January 2025 $17M PIPE Wellington Management, Eventide, Marshall Wace IPO Strong
12 HistoSonics Noninvasive tumor histotripsy platform $553M 7 October 2025 $250M Growth equity K5 Global, Bezos Expeditions, Wellington Management Acquired Strong
13 Impulse Dynamics Heart failure implant therapy $535M 6 December 2025 $158M Series F Sands Capital, Braidwell, Redmile Group Active Partial
14 PROCEPT BioRobotics Robotic BPH surgery system $513M 9 September 2023 $173M Post-IPO Equity Public investors, Perceptive Advisors, T. Rowe Price IPO Partial
15 CeQur Wearable insulin delivery patch $492M 6 June 2026 $100M Series E Endeavour Vision, Credit Suisse Entrepreneur Capital, Tandem Diabetes Care Active Strong
16 Kardium Atrial fibrillation ablation system $471M 6 July 2025 $250M Late-stage financing Janus Henderson Investors, Qatar Investment Authority, MMCAP Active Strong
17 Biofourmis Virtual care digital medicine $465M 7 August 2022 $20M Series D extension Intel Capital, General Atlantic, CVS Health Active Strong
18 Cornerstone Robotics Surgical robotics systems $459M 4 November 2025 $200M Series D / new financing HKIC, Qiming Venture Partners, Gaorong Capital Active Partial
19 RefleXion Medical Biology-guided cancer radiotherapy $449M 6 November 2023 $105M Equity Financing The Rise Fund, Ally Bridge, Pfizer Ventures Active Strong
20 Exo Handheld ultrasound platform $410M 5 May 2025 $100M Venture / extension Sands Capital, Bold Capital, Qubit Health Capital Active Partial
21 Kestra Medical Technologies Wearable cardiac defibrillator platform $398M 2 March 2025 $202M IPO Public investors IPO Strong
22 Distalmotion Dexter surgical robot $390M 6 January 2026 Undisclosed Strategic equity investment Johnson & Johnson Innovation – JJDC Active Partial
23 Cleerly AI coronary imaging $383M 4 December 2024 $106M Series C extension Insight Partners, Battery Ventures, T. Rowe Price Active Partial
24 Aidoc Clinical AI imaging platform $370M 7 2026 $150M Series E / Growth Goldman Sachs Alternatives, General Catalyst, SoftBank Active Partial
25 NeuroPace Responsive epilepsy neurostimulation $366M 9 April 2021 $102M IPO Accelmed, KCK Group, OrbiMed IPO Partial
26 JenaValve Transcatheter aortic valve replacement $364M 13 August 2022 $100M Series C Bain Capital Life Sciences, Andera Partners, Valiance Advisors Acquired Partial
27 Imperative Care Stroke thrombectomy devices $345M 4 July 2021 $260M Series D D1 Capital Partners, HealthCor, Innovatus Capital Active Partial
28 Synchron Endovascular brain-computer interfaces $345M 4 November 2025 $200M Series D Double Point Ventures, ARCH Venture Partners, Khosla Ventures Active Strong
29 Neko Health Preventive full-body health scans $325M 2 January 2025 $260M Series B Lightspeed Venture Partners, General Catalyst, Lakestar Active Full
30 Karius Genomic infectious disease diagnostics $315M 5 May 2024 $100M Series C Khosla Ventures, 5AM Ventures, Gilde Healthcare Active Strong
31 Science Corp Brain and retinal interfaces $303M 3 March 2026 $230M Series C Lightspeed Venture Partners, Khosla Ventures, Y Combinator Active Partial
32 Nalu Medical Chronic pain neurostimulation $289M 4 March 2024 $85M Series E Novo Holdings, B Capital, Gilde Healthcare Acquired Strong
33 Caresyntax Surgical intelligence software $288M 5 August 2024 $80M Series C extension Symbiotic Capital, BlackRock, Optum Ventures Active Partial
34 Mainstay Medical Low-back pain neurostimulation $284M 5 February 2024 $125M Public equity financing Gilde Healthcare, Viking Global, Ally Bridge Group IPO Partial
35 Biolinq Wearable metabolic biosensors $280M 5 April 2025 $100M Series C Alpha Wave Ventures, RiverVest, AXA IM Alts Active Strong
36 4C Medical Technologies Transcatheter heart valve therapies $255M 5 March 2025 $175M Series D Boston Scientific, MicroPort CardioFlow, Anges Québec Active Strong
37 PathAI AI pathology diagnostics platform $255M 5 May 2021 $165M Series C D1 Capital, Kaiser Permanente, General Atlantic Active Strong
38 SetPoint Medical Neuroimmune modulation for autoimmune disease $250M 4 August 2025 $115M Series D Elevage Medical Technologies, Ally Bridge Group, Abbott Active Partial
39 Viz.ai AI care coordination platform $250M 5 April 2022 $100M Series D Tiger Global, Insight Partners, Scale Ventures Active Full
40 Paige AI digital pathology software $241M 6 January 2023 $20M Strategic equity Microsoft Acquired Strong
41 Supira Medical Percutaneous ventricular assist devices $240M 5 March 2025 $120M Series E Novo Holdings, Qatar Investment Authority, Cormorant Asset Management Active Full
42 VitalConnect Wearable biosensor cardiac monitoring $240M 6 February 2025 $100M Series G Ally Bridge Group, EW Healthcare Partners, MVM Life Science Partners Active Partial
43 Orchestra BioMed Cardiovascular therapy device developer $220M 5 May 2026 $20M Public / corporate equity Medtronic, Ligand IPO Partial
44 Medical Microinstruments Robotic microsurgery platform $220M 4 February 2024 $110M Series C Fidelity, Deerfield, RA Capital Active Partial
45 Hyperfine Portable MRI imaging system $216M 2 December 2021 $126M PIPE / de-SPAC HealthCor, Catalio, PIPE investors IPO Partial
46 Pulnovo Medical Pulmonary hypertension device therapy $215M 4 April 2026 $100M Strategic Financing Medtronic, EQT, Qiming Venture Partners Active Strong
47 Blackrock Neurotech Brain-computer interfaces $210M 2 April 2024 $200M Strategic investment Tether Evo, re.Mind Capital, Peter Thiel Acquired Full
48 TytoCare Remote medical exam platform $205M 8 August 2023 $49M Series E / Growth Insight Partners, MemorialCare, HOOPP Active Strong
49 FIRE1 Heart failure monitoring $201M 5 January 2025 $120M Series D Polaris Partners, Elevage Medical Technologies, Sands Capital Active Partial
50 Galvanize Therapeutics Pulsed electric field therapies $200M 2 September 2025 $100M Series C Sofinnova Partners, Norwest Venture Partners, Janus Henderson Active Strong
51 CereVasc Minimally invasive hydrocephalus device $199M 3 June 2026 $85M Series C Piper Sandler Merchant Banking, JJDC, Medtronic Active Full
52 restor3d Personalized orthopedic implants $197M 4 August 2025 $104M Series B Partners Group, existing shareholders Active Partial
53 Carlsmed Personalized spine surgery $196M 5 July 2025 $101M IPO B Capital, USVP, public investors IPO Strong
54 Element Science Wearable defibrillator platform $193M 4 March 2020 $146M Series C Deerfield Healthcare, Qiming Venture Partners USA, Cormorant Active Partial
55 ForSight Robotics Robotic eye surgery $190M 3 June 2025 $125M Series B Eclipse, Adani Group, Reiya Ventures Active Full
56 Vicarious Surgical Single-port surgical robotics $188M 5 October 2025 $6M Post-IPO Equity Lake Street Capital Markets, BD, Khosla Ventures IPO Partial
57 OrganOx Organ preservation perfusion systems $187M 9 February 2025 $142M Equity financing HealthQuest, BGF, Lauxera Acquired Partial
58 Ronovo Surgical Modular surgical robotics platform $186M 6 September 2025 $67M Series D JJDC, Lilly Asia Ventures, INCE Capital Active Partial
59 SonoThera Ultrasound-guided gene therapy delivery $186M 2 June 2026 $125M Series B Vida Ventures, CureDuchenne Ventures, ARCH Venture Partners Active Strong
60 Magenta Medical Miniature heart pump $183M 5 July 2024 $105M Series D Novo Holdings, Viking Global, RA Capital Active Partial
61 MicroTransponder Stroke recovery VNS therapy $180M 10 March 2025 $65M Series F USVP, Gilde Healthcare, Longitude Capital Active Partial
62 Cardiac Dimensions Mitral repair implant $165M 5 March 2025 $53M Series E Ally Bridge Group, Lumira, Arboretum Active Partial
63 Precision Neuroscience Minimally invasive brain implants $155M 3 December 2024 $102M Series C General Equity Holdings, B Capital, Duquesne Family Office Active Full
64 Apreo Health Emphysema airway scaffold $153M 2 August 2025 $130M Series B Bain Capital Life Sciences, Norwest, F-Prime Active Partial
65 Noah Medical Robotic bronchoscopy platform $150M 1 April 2023 $150M Series B SoftBank Vision Fund, Prosperity7, Tiger Global Active Full
66 AliveCor Personal ECG monitoring $149M 6 August 2022 Undisclosed Series F GE HealthCare, Khosla Ventures, Qualcomm Ventures Active Partial
67 LightForce Orthodontics Custom 3D-printed braces $144M 3 August 2023 $80M Series D Ally Bridge Group, Transformation Capital, CareCapital Active Strong
68 Augmedics AR spine surgery navigation $142M 4 June 2023 $83M Series D CPMG, Evidity Health Capital, H.I.G. Capital Active Full
69 Capstan Medical Structural heart implants $141M 2 December 2024 $110M Series C Eclipse, Yu Galaxy, Intuitive Active Full
70 BioIntelliSense Medical-grade wearable monitoring $140M 4 December 2025 $58M Series C Philips, Chimera, 7wireVentures Active Strong
71 Healthy.io Smartphone kidney testing $140M 4 May 2023 $50M Series D Schusterman Family Investments, Aleph, existing shareholders Active Strong
72 Perspectum AI medical imaging diagnostics $140M 9 March 2023 $55M Series C Oppenheimer, HealthQuest, Blue Venture Fund Active Partial
73 CardioFocus Cardiac ablation systems $138M 4 February 2023 $32M Series E SV Health Investors, Kennedy Lewis, institutional syndicate Active Low
74 Eko Health AI digital stethoscopes $131M 4 June 2024 $41M Series D ARTIS Ventures, Highland Capital Partners, NTTVC Active Partial
75 Neuspera Medical Miniaturized neurostimulation implants $125M 5 July 2024 $23M Series D Vertex Ventures HC, Treo Ventures, Olympus Active Strong
76 Sight Diagnostics AI blood diagnostics platform $124M 4 August 2020 $71M Series D Koch Disruptive Technologies, Longliv Ventures, OurCrowd Active Strong
77 Qure.ai AI medical imaging diagnostics $121M 3 September 2024 $65M Series D Lightspeed, 360 ONE Asset, Merck GHI Active Strong
78 Proximie Connected surgical platform $119M 3 June 2022 $80M Series C Advent Life Sciences, SoftBank Vision Fund 2, Mubadala Active Full
79 Momentis Surgical Robotic surgical platform $117M 5 November 2023 $6M Series D extension Peregrine Ventures, Ceros, OurCrowd Active Partial
80 Think Surgical Orthopedic surgical robotics systems $105M 2 June 2023 $5M Strategic investment KDB Investment Global Healthcare, David Dvorak Active Partial
81 CoMind Non-invasive brain monitoring $103M 3 October 2025 $60M Series A second close Plural, Angelini Ventures, LocalGlobe Active Partial
82 Endotronix Heart failure monitoring $102M 2 October 2019 $70M Series D extension LSP/EQT Life Sciences, BioVentures Investors, Lumira Ventures Acquired Partial
83 Ultromics AI echocardiography heart diagnostics $102M 4 July 2025 $55M Series C L&G, Allegis Capital, Lightrock Active Strong
84 Amber Therapeutics Neuromodulation for incontinence $100M 2 June 2024 $100M Series A NEA, F-Prime Capital, Lightstone Ventures Active Strong
85 RapidAI Clinical AI imaging workflows $100M 2 July 2023 $75M Series C Vista Credit Partners, Lennertz & Co. Active Full
86 Notal Vision Remote retinal disease monitoring $89M 3 June 2021 $60M Series D Soleus Capital, Ganot Capital, Elron Active Partial
87 Paradromics Brain-computer interface implants $89M 12 February 2025 Undisclosed Series A extension Prime Movers Lab, Green Sands, Synergy Ventures Active Partial
88 Moon Surgical Collaborative surgical robotics $87M 2 May 2023 $55M Series B Sofinnova Partners, NVentures, GT Healthcare Active Strong
89 SPR Therapeutics Peripheral nerve stimulation pain relief $87M 3 February 2024 $25M Series D-1 equity Revelation Partners, RC Capital, Mutual Capital Partners Active Partial
90 Theranica Wearable migraine neuromodulation device $86M 4 August 2022 $45M Series C New Rhein Healthcare Investors, aMoon, Lightspeed Venture Partners Active Strong
91 Scopio Labs Digital microscopy and hematology AI $73M 3 February 2022 $50M Series C OurCrowd, Aurum Ventures, Ilex Medical Active Partial
92 FineHeart Implantable heart pump $73M 4 January 2026 $41M Series C Groupe Pasteur Mutualité, Groupe Etchart, EIC Fund Active Strong
93 Adagio Medical Cardiac cryoablation devices $72M 6 October 2025 $19M PIPE ArrowMark, RA Capital, Perceptive Advisors IPO Partial
94 WISE Implantable neurotechnology electrodes $62M 4 June 2026 $34M Series D ENEA Tech and Biomedical, CDP Venture Capital, Principia SGR Active Strong
95 Quibim AI imaging biomarkers $60M 4 January 2025 $50M Series A Asabys Partners, Buenavista, Amadeus Capital Active Partial
96 Materna Medical Women’s pelvic health devices $57M 5 July 2026 $5M Series B3 InnovaHealth Partners, Wavemaker360 Health, Band of Angels Active Partial
97 CroíValve Transcatheter tricuspid valve repair $45M 3 June 2026 $20M Series B expansion BGF, EIC Fund, MedTech Syndicate Active Strong
98 CardioMech Mitral valve repair $42M 3 January 2024 $13M Series B-style equity Hadean Ventures, Investinor, strategic investor Active Partial
99 LensGen Fluid-optic intraocular lens $41M 4 March 2023 $6M Bridge financing HOYA Group, Relativity Healthcare Partners, ExSight Ventures Active Strong
100 C2N Diagnostics Alzheimer’s blood diagnostics $35M 2 March 2025 $10M Strategic Equity Samsung Venture Investment, Samsung Biologics, Samsung C&T Active Low

Key funding trends in the MedTech market

Insights

  • The top 10 MedTech startups raised about $10.7B, or 35.4% of the total funding tracked, which shows how strongly capital concentrates around category leaders.
  • Cancer blood testing is one of the clearest mega-funding themes in MedTech, with Grail and Freenome alone raising about $3.0B across multi-cancer and early cancer diagnostics.
  • Neurotechnology has moved beyond niche device funding, with Neuralink, Synchron, Blackrock Neurotech, Precision Neuroscience, and WISE raising about $2.0B combined.
  • Surgical robotics remains extremely capital intensive, with CMR Surgical, Cornerstone Robotics, ForSight Robotics, Ronovo Surgical, Moon Surgical, and Vicarious Surgical representing a large funding cluster.
  • Wearable and remote-monitoring MedTech companies are scaling across consumer and clinical markets, led by Oura, Butterfly Network, BioIntelliSense, Healthy.io, Sight Diagnostics, and VitalConnect.
  • Cardiovascular devices remain a durable investor category, with strong funding across ablation, heart failure monitoring, valve repair, ventricular support, and coronary diagnostics.
  • Several MedTech startups raised very large totals across only a few rounds, including Neko Health, Noah Medical, Blackrock Neurotech, Galvanize Therapeutics, and Apreo Health.
  • AI diagnostics is no longer a small software subcategory, with HeartFlow, Cleerly, Aidoc, PathAI, Viz.ai, Qure.ai, and Ultromics all crossing meaningful funding thresholds.

A few word about our methodology

As you can see, we built a database that ranks startups in the MedTech market based on their total cumulative fundraising. To create this ranking, we reviewed many sources and cross-checked information across multiple places.

Whenever possible, we prioritized official company communications, since they are the most reliable source for funding amounts. When those were not available, we relied on reputable industry sources such as TechCrunch, Crunchbase, Financial Times or Forbes (to name a few).

We excluded random blogs, unverified websites, and any sources that could not be validated.

When funding rounds were announced in other currencies such as euros, Swiss francs, Singapore dollars, Australian dollars, or rupees, we converted them into approximate USD equivalents for consistency.

Sometimes different sources report slightly different numbers, or the exact round size is not fully disclosed. In those cases, we flag the uncertainty and assign a confidence label to each startup, visible in the last column.

Here is what they mean.

Full confidence: The company’s equity fundraising history can be reconstructed completely from public sources. The rounds, dates, amounts, and key investors are clearly identified, with no meaningful gaps.

Strong confidence: The fundraising history is largely complete and reliable. There may be a small missing detail, such as incomplete investor information or a minor round with limited data, but the overall record is clear.

Partial confidence: The main fundraising rounds can be identified, but the record is incomplete or somewhat mixed. Some rounds may be missing or certain funding events may be difficult to separate clearly.

Low confidence: Public information is too limited, inconsistent, or ambiguous to reliably reconstruct the company’s equity fundraising history.

When the confidence level is too low, we take a conservative approach and exclude the company from the ranking. We don’t want to include data that cannot be reliably verified.

In a world where LLMs hallucinate and unreliable information is everywhere, our goal is simple: provide data you can trust.

If you want the full detail on a specific calculation, feel free to contact us and we will gladly explain.

Finally, know that we update the dataset once per month, so come back here if you need fresh information.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page. You can also follow us on Instagram or on Facebook.

How we created this content 🔎📝

At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.

So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.

Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.

Back to blog